For a 45-year-old premenopausal woman with a 1.8 cm grade 1 hormone‑receptor‑positive, HER2‑negative, node‑negative invasive ductal carcinoma and a Recurrence Score of 18, is four cycles of adjuvant docetaxel‑cyclophosphamide (TC) the appropriate chemotherapy regimen?

TC Chemotherapy is Appropriate for This Patient

For this 45-year-old premenopausal woman with grade 1.8 cm, HR+/HER2-negative, node-negative invasive ductal carcinoma and a Recurrence Score of 18, four cycles of docetaxel-cyclophosphamide (TC) represents a reasonable chemotherapy regimen, though the decision to pursue chemotherapy at all warrants careful consideration given her low-intermediate risk profile.

Risk Stratification and Treatment Context

This patient falls into an intermediate-risk category based on ESMO criteria 1: she has a tumor >1 cm (1.8 cm) despite being grade 1 and node-negative. Her young age (45 years, premenopausal) and Recurrence Score of 18 place her in a zone where chemotherapy benefit remains uncertain but potentially meaningful.

The Critical Question: Does She Need Chemotherapy?

The TAILORx trial data established that premenopausal women under age 50 with RS 16-25 derive some benefit from chemotherapy 2, 3. Specifically:

• RS 16-20: Modest benefit in women <50 years
• RS 21-25: More substantial benefit in this age group
• RS 18: Falls in the lower end where benefit is less clear

Recent real-world data from the National Cancer Database showed that premenopausal patients (age ≤50) with RS 16-25 who received chemotherapy had improved overall survival, with hazard ratios favoring chemotherapy particularly in the RS 21-25 subgroup 2. However, at RS 18, the absolute benefit is likely small (approximately 2-4% improvement in distant recurrence-free survival at 10 years).

TC Regimen: Appropriate Choice IF Chemotherapy is Pursued

If the decision is made to proceed with chemotherapy, TC for 4 cycles is an acceptable regimen 4, 5, 6.

Evidence Supporting TC:

The 2018 ASCO guidelines explicitly state: "Docetaxel-cyclophosphamide × 4 is recommended as an alternative to doxorubicin-cyclophosphamide × 4 and offers improved disease-free survival and overall survival" 5. This is based on the US Oncology 9735 trial showing TC superiority over AC in early-stage breast cancer.

TC regimen specifics 4, 7:

• Docetaxel 75 mg/m² IV day 1
• Cyclophosphamide 600 mg/m² IV day 1
• Every 21 days for 4 cycles

Advantages of TC in This Context:

1. Avoids anthracycline cardiotoxicity: Critical for a young woman with decades of life expectancy
2. Shorter duration: 4 cycles vs. 6-8 cycles with anthracycline-taxane sequential regimens
3. Established efficacy: Category 1 recommendation in NCCN guidelines 6
4. Appropriate for HR+ disease: Non-anthracycline regimens are particularly suitable for hormone receptor-positive tumors where the absolute chemotherapy benefit is smaller 5, 8

Alternative Considerations and Caveats

The Case for Endocrine Therapy Alone:

Given her grade 1 histology (typically associated with excellent prognosis) and RS 18 (lower end of intermediate range), endocrine therapy alone is a legitimate alternative 1. ESMO guidelines suggest that intermediate-risk, endocrine-responsive tumors may be treated with "ET alone or CT/ET" 1.

Critical factors favoring endocrine therapy alone:

• Grade 1 disease (low proliferation)
• Node-negative status
• RS 18 (not 21-25 where benefit is clearer)
• Excellent long-term prognosis with endocrine therapy

If Anthracycline-Based Regimen Were Considered:

While NCCN lists dose-dense AC followed by paclitaxel as a "preferred regimen" 4, this is excessive for her risk profile. The 2011 NCCN guidelines note that "randomized clinical trials show that the addition of a taxane to anthracycline-based chemotherapy provides an improved outcome" 4, but this applies primarily to higher-risk populations.

For this patient, anthracycline-based regimens would be overtreatment given:

• Node-negative disease
• Grade 1 histology
• HR+ biology
• Unnecessary cardiotoxicity risk

Recommended Approach

The treatment algorithm should proceed as follows:

1. Confirm menopausal status and ensure accurate hormone receptor quantification (strong ER/PR positivity favors endocrine therapy alone)

2. Shared decision-making discussion addressing:

   • Absolute benefit of chemotherapy: likely 2-4% reduction in distant recurrence at 10 years
   • Toxicity burden: neuropathy, fatigue, alopecia, infection risk
   • Alternative: endocrine therapy alone with ovarian suppression

3. If chemotherapy is chosen: TC × 4 cycles is appropriate

   • Followed by endocrine therapy (tamoxifen + ovarian suppression or aromatase inhibitor + ovarian suppression for 5-10 years) 4, 6, 9
   • Chemotherapy should be completed before starting endocrine therapy 4, 1

4. If chemotherapy is declined: Aggressive endocrine therapy

   • Ovarian suppression (GnRH agonist) + aromatase inhibitor for 5 years minimum 6, 9
   • Consider extended duration to 7-10 years 9

Common Pitfalls to Avoid

1. Over-treating with anthracycline-based regimens: Grade 1, node-negative disease does not require TAC or dose-dense AC-T
2. Ignoring patient preference: At RS 18, the benefit is marginal—patient values must drive the decision
3. Forgetting ovarian suppression: In premenopausal women with intermediate-risk disease, ovarian suppression + AI improves outcomes 6, 9
4. Concurrent chemotherapy and endocrine therapy: These should be sequential, with endocrine therapy starting after chemotherapy completion 4, 1

In summary: TC × 4 is an appropriate chemotherapy choice if chemotherapy is pursued, but the fundamental question is whether chemotherapy adds sufficient benefit over endocrine therapy alone in this grade 1, RS 18 patient. Both approaches are defensible based on current evidence.